SKYRIZI VS OTEZLA® (apremilast)
SKYRIZI VS COSENTYX® (secukinumab)
SKYRIZI VS STELARA® (ustekinumab)
SKYRIZI VS HUMIRA® (adalimumab)

SKYRIZI VS HUMIRA® (adalimumab)2

SUPERIOR RATES OF PASI 90 AT WEEK 16
IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY

CO-PRIMARY ENDPOINTS IN ULTIMMA-1 AND ULTIMMA-2 (NRI)1,4

PASI 90 at Week 16
UltIMMa-1:
SKYRIZI 75% (229/304),
placebo 5% (5/102)
UltIMMa-2:
SKYRIZI 75% (220/294),
placebo 2% (2/98)

p<0.0001.

sPGA 0/1 at Week 16
UltIMMa-1:
SKYRIZI 88% (267/304), placebo 8% (8/102)
UltIMMa-2:
SKYRIZI 84% (246/294), placebo 5% (5/98)

NRI=Nonresponder imputation.

Study Design:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. Patients received SKYRIZI 150 mg at Week 0, Week 4, and every 12 weeks thereafter.1,4

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
PASI 90 PASI 90
PASI 100 PASI 100

In Part A of IMMvent,
a 2-part, Phase 3 study

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 90 VS HUMIRA® (adalimumab) AT WEEK 162

72% OF SKYRIZI PATIENTS ACHIEVED PASI 90 VS 47% OF HUMIRA PATIENTS (NRI)2

WEEK 16 RESULTS (PART A)

Chart depicting 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA patients (NRI). Chart depicting 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA patients (NRI). Chart depicting 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA patients (NRI).

*p<0.0001

 

Part A Co-Primary Endpoints: PASI 90 and sPGA 0/1 at Week 16

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.3

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.3

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Nonresponder imputation.

In Part B, HUMIRA patients who achieved PASI 50 to <90 were re-randomized 1:1

3x MORE PATIENTS ACHIEVED PASI 90 AFTER SWITCHING TO SKYRIZI THAN THOSE WHO REMAINED ON HUMIRA® (adalimumab)2

66% OF SKYRIZI PATIENTS ACHIEVED PASI 90 VS 21% OF HUMIRA PATIENTS (NRI)2

WEEK 44 RESULTS (PART B)

Chart depicting 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA patients (NRI). Chart depicting 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA patients (NRI). Chart depicting 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA patients (NRI).

*p<0.0001

 

PART B Primary Endpoint: PASI 90 at Week 44

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.3

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.3

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Nonresponder imputation.

Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See

Full Prescribing Information
VIEW PASI 100 DATA

In Part A of IMMvent,
a 2-part, Phase 3 study

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 100 VS HUMIRA® (adalimumab) AT WEEK 162

40% OF SKYRIZI PATIENTS ACHIEVED COMPLETE CLEARANCE (PASI 100) VS 23% OF HUMIRA PATIENTS (NRI)2

WEEK 16 RESULTS (PART A)

Chart depicting 40% of SKYRIZI® patients achieved complete clearance (PASI 100) vs 23% of Humira patients (NRI). Chart depicting 40% of SKYRIZI® patients achieved complete clearance (PASI 100) vs 23% of Humira patients (NRI). Chart depicting 40% of SKYRIZI® patients achieved complete clearance (PASI 100) vs 23% of Humira patients (NRI).

*p<0.0001

 

Part A Ranked Secondary Endpoints: PASI 75 and PASI 100 at Week 16

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.3

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.3

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Nonresponder imputation.

In Part B, HUMIRA patients who achieved PASI 50 to <90 were re-randomized 1:1

MORE PATIENTS ACHIEVED PASI 100 AFTER SWITCHING TO SKYRIZI THAN THOSE WHO REMAINED ON HUMIRA® (adalimumab)2

40% OF SKYRIZI PATIENTS ACHIEVED Complete clearance (PASI 100) VS 7% OF HUMIRA PATIENTS (NRI)2

WEEK 44 RESULTS (PART B)

Chart depicting 40% of Skyrizi patients achieved complete clearance (PASI 100) vs 7% of Humira patients (NRI) at week 44. Chart depicting 40% of Skyrizi patients achieved complete clearance (PASI 100) vs 7% of Humira patients (NRI) at week 44. Chart depicting 40% of Skyrizi patients achieved complete clearance (PASI 100) vs 7% of Humira patients (NRI) at week 44.

*p<0.0001

 

Part B Ranked Secondary Endpoint: PASI 100 at Week 44

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.3

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.3

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Nonresponder imputation.

Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See

Full Prescribing Information
VIEW PASI 90 DATA

Well-Studied Safety Profile

across 4 pivotal trials1

Review Safety

4 DOSES PER YEAR

4 doses per year after 2 initiation doses
at Weeks 0 and 4 (150 mg/dose)1

VIEW DOSING SCHEDULE